Independent directory Public ClinicalTrials.gov records United States
Clear filters

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 7:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,925 matching trials from the local directory fallback.
Conditions
Obesity, Type 2 Diabetes
Interventions
Cagrisema, Semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
99
States / cities
Birmingham, Alabama • Pelham, Alabama • Gilbert, Arizona + 81 more
Conditions
Idiopathic Short Stature, Short Stature Homeobox Gene Mutation, Small for Gestational Age at Delivery, Turner Syndrome
Interventions
Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector
Combination Product
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
2 Years to 17 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
23
States / cities
Palo Alto, California • Sacramento, California • Aurora, Colorado + 19 more
Conditions
Stargardt Disease
Interventions
AAVB-039
Biological
Lead sponsor
AAVantgarde Bio Srl
Industry
Eligibility
8 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more
Conditions
Geographic Atrophy, Macular Degeneration
Interventions
JNJ-81201887, Sham Procedure
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
60 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
45
States / cities
Tucson, Arizona • Fullerton, California • La Jolla, California + 40 more
Conditions
X-Linked Myotubular Myopathy
Interventions
No Intervention
Other
Lead sponsor
Astellas Gene Therapies
Industry
Eligibility
Up to 17 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Santa Monica, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Conditions
Locally Advanced Head and Neck Squamous Cell Carcinoma
Interventions
volrustomig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
69
States / cities
Birmingham, Alabama • Phoenix, Arizona • Prescott Valley, Arizona + 61 more
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab, Placebo
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
5 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 18 more
Conditions
Healthy
Interventions
Breast Milk Sampling, Nipocalimab
Other · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Relapsed Refractory Multiple Myeloma
Interventions
AZD0120, Bortezomib, Carfilzomib, Daratumumab, Dexamethasone, Pomalidomide
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
48
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 40 more
Conditions
Fragile X Syndrome
Interventions
High dose of MRM-3379, Low dose of MRM-3379, Low dose of MRM-3379 Open-Label, Middle Dose of MRM-3379, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
13 Years to 45 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Irvine, California • Orange, California + 12 more
Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
Abiraterone, Androgen Deprivation Therapy (ADT), Darolutamide, Prednisone/Prednisolone, Tulmimetostat
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • Iowa City, Iowa • Westwood, Kansas + 5 more
Conditions
NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), Non-Small Cell Lung Cancer
Interventions
daraxonrasib, docetaxel
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
45
States / cities
Birmingham, Alabama • Long Beach, California • New Haven, Connecticut + 38 more
Conditions
X-linked Retinoschisis
Interventions
ATSN-201
Biological
Lead sponsor
Atsena Therapeutics Inc.
Industry
Eligibility
5 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 14 more
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study of COVID-19 Vaccine(s) in Children and Adults

NCT07798648
Conditions
COVID-19 Vaccines
Interventions
BNT162b2
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
5 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
14
States / cities
Homestead, Florida • Miami Lakes, Florida • Atlanta, Georgia + 10 more
Conditions
HIV Infections
Interventions
CAB LA, CAB ULA, RPV LA, RPV ULA
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
12 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
40
States / cities
Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 34 more
Conditions
Lung Cancer, Lung Nodule
Interventions
Platelet RNA-based assay
Diagnostic Test
Lead sponsor
University of Utah
Other
Eligibility
21 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Salt Lake City, Utah
Conditions
Chronic Lymphocytic Leukemia
Interventions
Acalabrutinib, Sonrotoclax, Venetoclax, Zanubrutinib
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
22
States / cities
Duarte, California • Orange, California • Palo Alto, California + 19 more
Conditions
Acute Treatment of Migraine
Interventions
Zavegepant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 11 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Washington D.C., District of Columbia • Hinesville, Georgia • Minneapolis, Minnesota + 9 more
Recruiting Phase 2Phase 3 Interventional

Nectero EAST System Clinical Study

NCT06001918
Conditions
Abdominal Aortic Aneurysm
Interventions
Nectero EAST System
Drug
Lead sponsor
Nectero Medical, Inc.
Industry
Eligibility
21 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
40
States / cities
Scottsdale, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 32 more
Conditions
Urothelial Carcinoma
Interventions
MK-3120, Pembrolizumab, Zilovertamab vedotin
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
10
States / cities
Orange, California • San Francisco, California • Aurora, Colorado + 7 more
Conditions
Carcinoma, Non-small-Cell Lung
Interventions
Amivantamab, Carboplatin, Direct Oral Anticoagulant (DOAC), Lazertinib, Low Molecular Weight Heparin (LMWH), Pemetrexed
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
26
States / cities
La Jolla, California • Orange, California • Stanford, California + 21 more
Conditions
Scoliosis Idiopathic
Interventions
Anterior Vertebral Body Tethering
Device
Lead sponsor
Pediatric Spine Foundation
Other
Eligibility
Up to 18 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
11
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Saint Paul, Minnesota + 8 more
Conditions
Healthy Volunteers
Interventions
INS1033, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 50 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Multiple Myeloma
Interventions
JNJ-79635322, Teclistamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Springdale, Arkansas + 38 more